The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback